|  |
| --- |
| **Table 2:** Adverse events in sunitinib-treated patients classified by age |
| **Adverse Event** | **Variable** | **p values** |
| **Age < 75 years (n=38)** | **Age ≥ 75 years (n=9)** |
|   | **All grade** | **≥Grade 3** | **All grade** | **≥ Grade 3** | **All grade** | **≥ Grade 3** |
| **Symptoms, n(%)** |  |  |  |  |  |  |
|  Nausea | 20(53) | 0(0) | 3(33) | 0(0) | 0.2977 | - |
|  Fever | 16(42) | 0(0) | 3(33) | 0(0) | 0.6297 | - |
|  Fatigue | 15(39) | 0(0) | 3(33) | 0(0) | 0.7333 | - |
|  Anorexia | 15(39) | 2(5) | 3(33) | 2(22) | 0.7333 | 0.1011 |
|  Hand-foot syndrome | 14(37) | 3(8) | 4(44) | 2(22) | 0.6731 | 0.216 |
|  Hypertension (de novo) | 14(37) | 2(5) | 4(44) | 0(0) | 0.6731 | 0.4818 |
|  Stomatitis | 13(34) | 2(5) | 3(33) | 1(11) | 0.9602 | 0.5187 |
|  Diarrhea | 10(26) | 0(0) | 3(33) | 1(11) | 0.6722 | 0.0378 |
|  Peripheral edema | 6(16) | 0(0) | 2(22) | 0(0) | 0.6443 | - |
|  Gastrointestinal hemorrhage | 5(13) | 1(3) | 2(22) | 0(0) | 0.4922 | 0.6228 |
| **Abnormal laboratory data, n(%)** |  |  |  |  |  |  |
|  AST increased  | 31(82) | 2(5) | 8(89) | 0(0) | 0.5998 | 0.4818 |
|  ALP increased  | 25(66) | 1(3) | 6(67) | 0(0) | 0.9602 | 0.6228 |
|  Platelet count decreased | 24(63) | 14(37) | 7(78) | 3(33) | 0.4053 | 0.8438 |
|  ALT increased  | 22(58) | 3(8) | 6(67) | 0(0) | 0.6297 | 0.3837 |
|  Hypothyroidism\* | 21(55) | 2(5) | 2(22) | 0(0) | 0.0746 | 0.4818 |
|  Creatinine increased  | 20(53) | 1(3) | 4(44) | 0(0) | 0.8349 | 0.6382 |
|  Neutrophil count decreased | 19(50) | 10(26) | 6(67) | 3(33) | 0.3676 | 0.6722 |
|  Leukocyte count decreased | 17(45) | 11(29) | 6(67) | 3(33) | 0.2367 | 0.7959 |
|  Hyponatremia | 17(45) | 4(11) | 4(44) | 0(0) | 0.9354 | 0.3019 |
|  Blood urea nitrogen increased  | 16(42) | 1(3) | 5(56) | 0(0) | 0.506 | 0.618 |
|  Hypocalcemia | 15(39) | 1(3) | 4(44) | 0(0) | 0.7847 | 0.6228 |
|  Hypophosphatemia | 14(37) | 4(11) | 2(22) | 0(0) | 0.4053 | 0.3089 |
|  Hyperkalemia | 13(34) | 0(0) | 3(33) | 0(0) | 0.9602 | - |
|  Gamma-GTP increased  | 12(32) | 2(5) | 2(22) | 0(0) | 0.581 | 0.4818 |
|  Serum amylase increased  | 12(32) | 3(8) | 2(22) | 0(0) | 0.581 | 0.3837 |
|  Hyperuricemia | 12(32) | 0(0) | 2(22) | 0(0) | 0.7132 | - |
|  Hypercalcemia | 9(24) | 0(0) | 1(11) | 0(0) | 0.4073 | - |
|  Hypokalemia | 8(21) | 1(3) | 1(11) | 0(0) | 0.4955 | 0.6228 |
|  lipase Increased | 6(16) | 3(8) | 2(22) | 1(11) | 0.6443 | 0.7559 |
|  Total bilirubin increased | 6(16) | 0(0) | 2(22) | 0(0) | 0.6443 | - |
| Graded according to CTCAEv3.0, and occurring in at least 20% of patients, or including patients with grade 3 or 4 adverse events. \*: Hypothyroidism consists of thyroid hormone decreased and thyroid-stimulating hormone increased, and most patients received medication before symptom appearance. **Abbreviations:** AST: aspartate aminotransferase; ALP: alkaline phosphatase; ALT: alanine aminotransferase; GTP: glutamyl transpeptidase |
|
|
|